View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 19, 2018

Lumendi secures CE-Mark for DiLumen EIP device

UK-based Lumendi has obtained the European CE-Mark for its DiLumen Endolumenal Interventional Platform (EIP) as an endoscope accessory.

UK-based Lumendi has obtained the European CE-Mark for its DiLumen Endolumenal Interventional Platform (EIP) as an endoscope accessory.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The device is a non-sterile, single-use, close-fitting sleeve intended to enable complete positioning of a conventional endoscope in the large intestine and aid in optical visualisation, diagnosis and treatment.

Following the CE-Mark approval, Lumendi is set to commercially launch the device in the European Union (EU) market, for which the company is currently developing a distribution network.

The company said that it has already established distributors for Italian and British regions.

Lumendi CEO Peter Johann said: “Receiving approval to apply the CE-Mark in Europe is critical to Lumendi ’s overall global strategy to open markets around the world to continue improving endoscopic interventions and migrating many gastrointestinal surgeries to less invasive endolumenal procedures.

“We are building a team to support our distributors in Europe in both marketing and clinical application.”

“To make the DiLumen EIP platform available across the EU, we are building a team to support our distributors in Europe in both marketing and clinical application.”

DiLumen is the initial device under the Endolumenal Interventional Platform that is part of Lumendi ‘s aim to switch various gastrointestinal surgeries to endolumenal procedures.

An endolumenal approach is expected to minimise general anaesthesia requirement, allow incisionless approach, decrease complications found with open or laparoscopic surgery, shorten hospital stays and reduce costs.

DiLumen EIP consists of two balloons that, when deployed and inflated, stabilise the area in between them. This therapeutic zone (TZ) is said to also allow insufflation and manipulation of the tissue.

The device is said to have been used to perform more than 400 procedures in the US to date.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network